TB prevalence | TB prevalence | TB prevalence | TB prevalence | TB prevalence | TB prevalence | TB prevalence | TB prevalence | TB prevalence |
Reference | Exposure | Clinical TB signs | Confirmed TB infection | Mortality | TB detection | Sample size | Data collection | Comments |
Alexander et al., 2002 | 100% | 100% | N = 1 | 100% | Signs, PM, MC | N = 20 | 1998/1999 | Tracking TB spread through 1 group following immigration of positive individual |
Drewe, Foote et al., 2009 | n.r. | 91.2% | 91.2% | 91.2% | PM, MC | N = 57 | 2005 - 2007 | Detailed pathology of 52 individuals euthanized for TB (5 individuals as control) |
Drewe, Dean et al., 2009 | 46.7%* | n.r. | 13.2% | n.r. | MC, IRT | N = 240 | 2005 - 2007 | Exposure determined by immune-reaction assay |
Drewe 2010 | n.r. | n.r. | 9% to 33% | n.r. | MC, IRT | N = 110 | 2006/2007 | TB transmission study, prevalence reported in 3 months periods |
Drewe et al., 2011 | 30%* | n.r. | n.r. | n.r. | MC, IRT | N = 134 | 2006/2007 | Exposure determined by immune-reaction assay, longitudinal testing of 37 individuals |
Clarke et al., 2016 | n.r. | n.r. | 34.7% | n.r. | IRT | N=108 | 2014/2015 | TB detected by immune-reaction assay, 24.7% to 82.4% depending on estimated exposure risk |
Patterson et al., 2017 | n.r. | 6% | 6% | 6% | Signs | N = 2388 | 2001 - 2015 | TB defined as clinical signs followed by TB related euthanasia |
Patterson et al., 2021 | n.r. | 17.5% | 8.95% | 11.1% | PM, MC, IRT, PCR | N = 268 | 2014 - 2016 | TB detection assay validation |
Patterson et al., 2022 | n.r. | n.r. | n.r. | 19% | MC, IRT | N = 135 | 2014 - 2016 | Intervention study |
Duncan et al., 2021 | n.r. | 63% (group level) | n.r. | 63% (group level) | Signs | N = 98 groups | 1993 - 2019 | TB effect on demography |
Donadio et al., 2022
|
100%
|
56.1%
|
60.6%
|
27.3%
|
Signs, PCR
|
N = 66
|
1998 - 2018
|
TB detection assay validation; individuals selected for likely TB exposure and signs; TB infections: 53% signs + PCR, 7.6% PCR only |
present study | 71% | 16.1% | n.r. | 11.6% | Signs | N = 3420 | 1993 - 2020 | TB quantification |
B) TB progression | B) TB progression | B) TB progression | B) TB progression | B) TB progression | B) TB progression | B) TB progression | B) TB progression | B) TB progression |
Reference | Exposure – infection | Exposure - signs | Infection - signs | Signs - death | TB detection | Sample size | Data collection | Comment |
Alexander et al., 2002 | n.r. | ~6 and 14 m | n.r. | n.r. | Signs, PM, MC | N = 20 | 1998/1999 | See above |
Drewe 2010 | 10m (1.5-25.3m) | n.r. | n.r. | MC, IRT | N = 110 | 2006/2007 | See above | |
Drewe et al., 2011 | 12.6m | n.r. | n.r. | 8.1m (infection to death) | MC, IRT | N = 134 (37 longitudinal testing) | 2006/2007 | See above |
Patterson et al., 2017 | n.r. | n.r. | n.r. | < 6 months | Signs, TB related euthanasia | N = 2388 | 2001 - 2015 | See above |
Duncan et al., 2021 | n.r. | n.r. | n.r. | 10 months (group level) | Signs | N = 98 groups | 1993 - 2019 | See above |
Donadio et al., 2022 | 14.0 ± 10.8m | n.r. | 11.5 ± 6.9m | 5.3 ± 5.7m | Signs, PCR | N = 66 | 1998 - 2018 | See above |
Present study | n.r. | 17.1 ± 13.8m | n.r. | 6.6 ± 10.8m | Signs | N = 3420 | 1993 - 2020 | See above |
Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies | Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies |